CFDE Data Portal | Search NDUFV1-DT

	Label	Description
	NDUFV1-DT Gene (Entity type)	ENSG00000184224 - NDUFV1 divergent transcript
	GSE213588 trametinib NF1 8 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE168745 H-7 JHH-7 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212330 azacitidine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

NDUFV1-DT

ENSG00000184224 - NDUFV1 divergent transcript

GSE213588 trametinib NF1 8 v 11 human up

A Gene Set from LINCS

GSE195663 cisplatin 0 v 1 human up

A Gene Set from LINCS

GSE216043 cisplatin 11 v 2 human dn

A Gene Set from LINCS

GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn

A Gene Set from LINCS

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human up

A Gene Set from LINCS

GSE168745 H-7 JHH-7 0 v 1 human dn

A Gene Set from LINCS

GSE212330 azacitidine 1 v 0 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.